The Food and Drug Administration yesterday approved a mobile medical application to help increase retention in outpatient treatment programs for opioid use disorder. The app can be downloaded to a patient’s mobile device with a prescription from his/her doctor to use while participating in an outpatient treatment program under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management. “As part of our efforts to address the misuse and abuse of opioids, we’re especially focused on new tools and therapies that can help more people with opioid use disorder successfully treat their addiction,” said FDA Commissioner Scott Gottlieb, M.D. “Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in contributing to these treatment efforts.”

Related News Articles

Headline
The National Institutes of Health April 3 released a study that found an artificial intelligence screening tool was as effective as health care providers in…
Headline
The Department of Health and Human Services March 18 announced that it renewed the public health emergency for the nation’s opioid crisis an additional 90 days…
Headline
The Department of Health and Human Services Office of Inspector General Feb. 18 released a report that found about 40% of Medicare enrollees who began opioid…
Headline
Today the Drug Enforcement Administration and Department of Health and Human Services announced that the effective date for the final rule regarding…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…